A new experimental drug, daraxonrasib, has shown significant promise in improving survival rates for patients with advanced pancreatic cancer, potentially extending its effectiveness to lung and ovarian cancers. Presented at the ASCO meeting, the drug targets a mutated protein responsible for tumor growth, offering hope for better treatment options.

• 01Daraxonrasib improved median survival for pancreatic cancer patients from 6.7 months to 13.2 months compared to chemotherapy.
• 02The drug targets the KRAS mutation found in over 90% of pancreatic cancer cases, which has been challenging to treat.
• 03Patients taking daraxonrasib reported fewer severe side effects and better quality of life than those receiving traditional chemotherapy.
• 04The clinical trial involved approximately 500 patients with metastatic pancreatic cancer.
• 05Researchers are investigating the drug's potential use earlier in treatment and for other cancers, including lung and ovarian.

The introduction of daraxonrasib could significantly change treatment protocols for pancreatic cancer, improving survival rates and quality of life for patients.